228 related articles for article (PubMed ID: 2534915)
1. Clinical trials referral resource. Adjuvant therapy of breast cancer.
Cheson BD
Oncology (Williston Park); 1989 Jun; 3(6):70-1, 74-5, 78. PubMed ID: 2534915
[No Abstract] [Full Text] [Related]
2. Clinical trials referral resource. High priority trials--III. Breast cancer.
Cheson BD; Ungerleider RS
Oncology (Williston Park); 1992 Dec; 6(12):46-50. PubMed ID: 1334690
[No Abstract] [Full Text] [Related]
3. Evolving concepts in the systemic adjuvant treatment of breast cancer.
Bonadonna G
Cancer Res; 1992 Apr; 52(8):2127-37. PubMed ID: 1559216
[No Abstract] [Full Text] [Related]
4. Adriamycin, vincristine, cyclophosphamide and 5-fluorouracil (AVCF) compared with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in premenopausal breast carcinoma. Personal results.
Mathé G; Misset JL; Plagne R; Reizenstein P; Belpomme D; Le Mevel B; Guerrin J; Fumoleau P; Metz R; Delgado M
Drugs Exp Clin Res; 1986; 12(1-3):143-5. PubMed ID: 3525068
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant systemic therapy in primary breast cancer.
Mouridsen HT; Palshof T
Acta Chir Scand Suppl; 1984; 519():43-53. PubMed ID: 6393664
[No Abstract] [Full Text] [Related]
6. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
[TBL] [Abstract][Full Text] [Related]
7. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials.
Taghian A; Jeong JH; Mamounas E; Anderson S; Bryant J; Deutsch M; Wolmark N
J Clin Oncol; 2004 Nov; 22(21):4247-54. PubMed ID: 15452182
[TBL] [Abstract][Full Text] [Related]
8. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).
Davidson NE; O'Neill AM; Vukov AM; Osborne CK; Martino S; White DR; Abeloff MD
J Clin Oncol; 2005 Sep; 23(25):5973-82. PubMed ID: 16087950
[TBL] [Abstract][Full Text] [Related]
9. [Adjuvant therapy of breast cancer].
Semiglazov VF; Abzumanov AS; Bozhok AA; Ivanov VG; Ivanova OA; Barash NIu; Topuzov EE; Seleznev IK; Migmanova NSh; Popova RT; Nurgaziev KSh
Khirurgiia (Mosk); 2001; (5):52-60. PubMed ID: 11505673
[No Abstract] [Full Text] [Related]
10. Effect of tamoxifen after chemotherapy in hormone receptor-positive, node-negative breast cancer.
Panasci LC
J Clin Oncol; 2006 May; 24(15):2392; author reply 2392. PubMed ID: 16710042
[No Abstract] [Full Text] [Related]
11. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
12. Early experiences of breast-conservation treatment combined with tamoxifen and CAF chemotherapy for breast cancer of stages I and II.
Ogawa Y; Nishioka A; Inomata T; Hamada N; Terashima M; Yoshida S; Tanaka Y; Ogoshi S; Araki K; Kumon M
Radiat Med; 1994; 12(1):29-35. PubMed ID: 8016401
[TBL] [Abstract][Full Text] [Related]
13. [Adriamycin/cyclophosphamide: current standard in adjuvant therapy for breast carcinoma?].
Sauter C
Schweiz Med Wochenschr; 1994 Oct; 124(43):1879-81. PubMed ID: 7973513
[No Abstract] [Full Text] [Related]
14. Breast conservation after induction chemotherapy for locally advanced breast cancer.
Kling KM; Ostrzega N; Schmit P
Am Surg; 1997 Oct; 63(10):861-4. PubMed ID: 9322658
[TBL] [Abstract][Full Text] [Related]
15. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
16. [Quandrantectomy in the conservative treatment of breast carcinoma].
Arrigoni F; Ventriglia L; Saturno F; Poletti EM; Sacco R
G Chir; 1993 Feb; 14(2):124-7. PubMed ID: 8489895
[TBL] [Abstract][Full Text] [Related]
17. [Importance of dose intensity in chemotherapy--lessons from adjuvant chemotherapy for early breast cancer].
Tamura K
Rinsho Ketsueki; 2009 Apr; 50(4):276-81. PubMed ID: 19404020
[No Abstract] [Full Text] [Related]
18. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant chemotherapy of axillary node-negative carcinoma of the breast using doxorubicin and cyclophosphamide.
Brooks RJ; Jones SE; Salmon SE; Chase EM; Davis SL; Moon TE; Giordano GF; Ketchel SJ; Jackson RA
NCI Monogr; 1986; (1):135-7. PubMed ID: 3534586
[TBL] [Abstract][Full Text] [Related]
20. [Effects of neoadjuvant intra-arterial infusion chemotherapy in patients with stage III breast carcinoma].
Higuchi K; Onda M; Furukawa K; Minobe K; Tanaka N; Arima Y; Hasegawa H
Gan To Kagaku Ryoho; 1997 Sep; 24(12):1799-802. PubMed ID: 9382536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
